Search PubMed⌕ Search

Biomedical subjects

H Wakasugi

Publications and source records attributed to H Wakasugi.

At least 145 records · Page 8Linked to original sources
PubMed1981

Clinical study of exocrine pancreatic function test by oral administration by N-benzoyl-L-tyrosyl-p-aminobenzoic acid.

The clinical usefulness of a simple exocrine pancreatic function diagnostic test (PFT) was examined by the oral administration of 500 mg of N-benzoyl-L-tyrosyl-p-aminobenzoic acid. Recovery of p-aminobenzoic acid (PABA) in the urine was significantly lower in patients with calcifying chronic pancreatitis (58.6%) and noncalcifying chronic pancreatitis (68.6%) than in healthy normal subjects (81.0%; p less than 0.001 and p less than 0.05, respectively). Abnormally low values were demonstrated in 15 out of 19 (78.9%) chronic pancreatitis cases. In comparing the PFT with the pancreozymin secretin test, a good correlation (P less than 0.001) with maximum bicarbonate concentration was detected. In cases which were abnormal with respect to the PFT, the recovery rate of PABA was increased by the administration of antacids or digestive enzyme preparations (average increase of 24.1 or 29.8%, respectively). These results suggest that this test is also useful for the evaluation of therapeutic effects in patients with pancreatic diseases.

4-Aminobenzoic Acid↗
PubMed1980

Biochemical and clinical studies on human pancreatic deoxyribonuclease I inhibitor.

Human pancreatic Deoxyribonuclease I (DNase I), inhibitor was partially purified from duodenal juice of healthy subjects collected in the Pancreozymin-Secretin test, by a procedure which included ammonium sulfate fractionation, DEAE cellulose fractionation, Sepharose 4B affinity chromatography, and gel filtration. The final preparation inhibited DNase I only, and had no inhibitory activity on pancreatic RNase, and trypsin. The inhibitor had a molecular weight of approximately 40,000, as determined by gel filtration, and showed the same mobility as skeletal muscle actin on SDS gel electrophoresis. Then clinical studies were made on the DNase I inhibitor in duodenal juice obtained after administration of Pancreozymin and Secretin to patients with various pancreatic diseases. In patients with suspected chronic pancreatitis with whom the ordinary test, containing the assay of the total volume, amylase output and maximum bicarbonate concentration of duodenal juice had produced normal results, the DNase I inhibitor output was observed to be higher than that in control subjects. While it was lower in patients with confirmed chronic pancreatitis than in control subjects. There results imply that DNase I inhibitor output may be an indicator of the pancreatic inflammation state and be useful for the early detection of pancreatic diseases.

Cholecystokinin↗
PubMed1980

Studies on serum immunoreactive elastase in experimental pancreatitis rats. I. In acute pancreatitis.

A new radioimmunological method for determination of serum rat elastase was described and serum elastase levels were measured in two different stages of acute pancreatitis: acute edematous and haemorrhagic pancreatitis were induced by PDL and PDLD technique in rats. In edematous pancreatitis, serum elastase levels showed a significant increase (P < 0.001) at one hour after induction of pancreatitis. Compared with control rats, whereas the serum amylase levels did not show a significant increase. In haemorrhagic pancreatitis, the levels of both elastase and amylase markedly increased within one hour of induction pancreatitis. These results show that the measurement of elastase level offers a more specific and sensitive parameter of diagnosis of acute pancreatitis than does amylase estimation.

Acute Disease↗
PubMed1980

Studies on serum immunoreactive elastase in experimental pancreatic rats. II. In chronic pancreatitis.

In this study using radioimmunoassay for rat, the relationship between the changes of elastase levels and the histological changes of pancreas demonstrated in two different cases of experimental chronic pancreatitis induced by dl-ethionine or PDL technique, and the resulting elastase levels were compared with amylase levels. In some of the Ethionine rats, serum elastase showed a high level, whereas serum amylase exhibited a significant decrease. In PDL rats at 3 days after ligation, elastase levels were higher than in other control rats. In PDL rats at 2, 4, and 8 weeks after ligation, serum elastase levels had significantly decreased, whereas amylase levels had not changes significantly when compared with the control rats. The changes of serum elastase levels in two different cases of experimental chronic pancreatitis showed some relation to the histological changes of the pancreas, while changes in serum amylase levels were not exhibited.

Amylases↗
PubMed1979

Clinical studies on carcinoembryonic antigen in pancreatic cancer.

We studied serum carcinoembryonic antigen (CEA) levels in 82 patients. Thirty-four of these had benign diseases while 48 had malignant diseases. Highest incidence and levels of CEA occurred in the sera of patients with pancreatic cancer and stomach cancer. In this paper we focused our particular attention on the serum CEA of 25 pancreatic cancer patients, and examined differences in serum CEA levels in relation to histologic differentiation and sites of pancreatric cancer. No statistical difference in serum CEA level was found among various histologic types and sites of the pancreatic cancer. Clinical courses of two patients with pancreatic cancer were also studied. Serial determinations of CEA levels are most useful in assessing the effect of operation or chemotherapies and are a useful indicator for differentiating pancreatic cancer from chronic pancreatitis but cannot be a conclusive factor for the diagnosis. Finally, we correlated serum CEA levels with those of RNase and confirmed a positive correlation.

Carcinoembryonic Antigen↗
PubMed1979

Clinical investigation of serum deoxyribonuclease: I. Analysis of serum deoxyribonuclease activity in comparison with normal and after endoscopic retrograde pancreatography.

Serum Deoxyribonuclease (DNase) micro-assay method was developed using 32P-labelled E. coli DNA as substrate. The serum DNase showed maximum activity at pH 7.5. It required Mg+ for activity, and was inhibited by EDTA or EGTA. The enzyme was also inhibited by actin (60-65%) or bovine pancreatic DNase I antibody (40-45%). The serum DNase activity was markedly increased following endoscopic retrograde pancreatography (ERP) examination. These results imply that serum DNase activity is mostly at least 60-65% pancreatic DNase I.

Actins↗
PubMed1979

Clinical investigation of serum deoxyribonuclease: II. Clinical studies of serum deoxyribonuclease activity in pancreatic disease.

Serum Deoxyribonuclease (DNase) of normal persons and of patients with chronic pancreatitis, pancreatic cancer, Diabetes Mellitus, or other malignant diseases was determined with (32P) DNA as substrate. Serum DNase activity was much lower in patients with chronic pancreatitis, pancreatic cancer, or other malignant diseases than in control subjects, and serum DNase activity was almost normal in patients with Diabetes Mellitus. There was no correlation between serum DNase and serum amylase, but there was a good correlation between serum DNase and DNase I output in duodenal juice. There was an inverse correlation between serum DNase and serum RNase. These results imply that in the diagnosis of possible pancreatic disorders serum DNase may be a good indicator and thus may be useful for the detection of malignant diseases.

Amylases↗
PubMed1979

Clinical studies on human pancreatic deoxyribonuclease I.

Duodenal juice collected after administration of Boot's pancreozymin and secretin to patients with various pancreatic diseases was subjected to deoxyribonuclease I (DNase I) assay, as well as measurements of total volume, amylase output and maximum bicarbonate concentration. It was observed that the DNase I output is well correlated with each of three factors. The DNase I output was much lower in patients with chronic pancreatitis or pancreatic cancer than in control subjects, and DNase I output was even found to be low in patients suspected of having chronic pancreatitis, who did not give abnormal resulsts with other assay methods. These results imply that DNase I output may be a good indicator of exocrine function of the pancreas, and thus may be useful for early detection of pancreatic diseases.

Amylases↗
PubMed1978

Serum ribonucleases in pancreatic cancer: relation to tumor histology.

Serum Ribonuclease (RNase, EC. 3. 1. 4. 22) of normal persons and of patients with chronic pancreatitis, or pancreatic cancer was determined with poly (C) as substrate. Strikingly abnormal elevations occured in the serum RNase of patients with pancreatic cancer (p less than 0.001). Average serum RNase values of 18 normal persons, 10 patients with chronic pancreatitis and 26 patients with pancreatic cancer were 92, 118, and 249 units, respectively. In patients with pancreatic cancer, we compared the RNase level with four histologic types (ductar cell adenocarcinoma, anaplastic cell carcinoma, acinar cell carcinoma, and islet cell carcinoma). Adenocarcinoma showed higher activity than the other histologic types (p less than 0.005). When we compared the serum of pancreatic cancer and pancreatic cancer tumor extract with normal serum and normal pancreas extract, strikingly different phosphocellulose chromatographic pattern were evident. The correlation of increased serum RNase levels with tumor histology and different chromatographic pattern may explain the new enzyme production in cancer patients, and have biological significance in the development of pancreatic cancer.

Adenoma, Islet Cell↗